Revolution Medicines, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Revolution Medicines, Inc. (RVMD) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $22.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-25
- Revolution Medicines, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Revolution Medicines, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $44.58M.
- Revolution Medicines, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Revolution Medicines, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-03-31 was $286.00K.
- Revolution Medicines, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $22.46M, a 49.62% decline from fiscal 2024.
- Revolution Medicines, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $44.58M, a 76.41% increase from fiscal 2023.
- Revolution Medicines, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $25.27M.
- Revolution Medicines, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $22.46M 10-K · filed 2026-02-25 | ||
| 2025-09-30 | $22.46M 10-Q · filed 2025-11-05 | |||
| 2024-12-31 | $44.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $44.58M 10-K · filed 2026-02-25 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $25.27M 10-K · filed 2026-02-25 | |||
| 2023-03-31 | $286.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $35.44M 10-K · filed 2024-02-26 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $21.19M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $21.19M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $21.19M 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |